Abstract: The present disclosure refers to an apparatus for updating an image section, comprising a head with at least one first image capturing device, in particular in form of a mirror head, configure to rotate between a plurality of positions in order to obtain a first field-of-view (FOV); at least one second image capturing device, in particular comprising a camera module, configured to capture a second field-of-view (FOV) different than the first FOV; and an electronic control unit (ECU) configured to adjust the second image capturing device to capture the second FOV and update a display unit to exhibit the image section with the second FOV. It also refers to a rear view device with such an apparatus and a method for updating an image section.

Abstract: An apparatus and methods for cold spraying with a spraying unit, a particle supply, a gas supply, and at least one heating unit. The heating unit contains a graphite felt that can be heated with an electric heater current, through which a gas stream can flow, wherein the at least one heating unit is arranged separately and/or in a pressure tank through which the gas stream can flow.

Abstract: An apparatus and methods for cold spraying with a spraying unit, a particle supply, a gas supply, and at least one heating unit. The heating unit contains a graphite felt that can be heated with an electric heater current, through which a gas stream can flow, wherein the at least one heating unit is arranged separately and/or in a pressure tank through which the gas stream can flow.

Abstract: The present invention relates to a new crystalline polymorph B-52 form of atorvastatin hemicalcium salt [A[(3R,5R)-7-[3-phenyl-4-[(phenyl carbamoyl]-2-(4-fluorophenyl)-5-(1-methylethyl)-1H-pyrrole-1-yl]-3,5-dihydroxy-heptanoic acid calcium salt (2:1)], medicinal preparations containing the new polymorph form, process for the preparation thereof and the use of the new polymorph form for the preparation of medicinal products.

Abstract: The invention refers to a novel process for the preparation of {2-[-(?-phenyl-p-chlorobenzyl)piperazin-1-yl]ethoxy}acetic acid, which comprises hydrolyzing an N,N-disubstituted {2-[-(?-phenyl-p-chlorobenzyl)piperazin-1-yl]ethoxy}acetamide, wherein said substituents are selected from alkyl groups having 1 to 4 carbon atoms optionally substituted by a phenyl group, alkenyl groups having 2 to 4 carbon atoms or cyclohexyl groups, or the substituents together with the adjacent nitrogen atom of the acetoamido group, form a morpholino group.

Abstract: The invention relates to high purity (1R,2S,4R)-(−)-2-[(2′-{N,N-dimethylamino}-ethoxy)]-2-[phenyl]-1,7,7-tri-[methyl]-bicyclo[2.2.1]heptane and pharmaceutically acceptable acid addition salts thereof containing not more than 0.2% of (1R,3S,4R)-3-[(2′-{N,N-dimethylamino}-ethyl)]-1,7,7-tri-[methyl]-bicyclo[2.2.1]heptane-2-one and/or of a pharmaceutically acceptable acid addition salt thereof. Furthermore the invention is concerned with a process for the preparation of these compounds. Moreover the invention relates to medicaments containing 1 or more of these compounds and their use.

Abstract: The invention refers to a novel process for the preparation of cetirizine of formula (I) as well as to novel {2-[4-(&agr;-phenyl-p-chloro-benzyl)piperazin-1-yl]ethoxy}acetamides of formula II, wherein R1 and R2 represent, independently, a C1-4 alkyl group optionally substituted by a phenyl group, a C2-4 alkenyl group or a cyclohexyl group, or R1 and R2 form together with the adjacent nitrogen atom a morpholino group. According to the novel process, an acetamide of formula (II) is hydrolized, if desired in the presence of a phase transfer catalyst, to obtain cetirizine.

Abstract: The invention relates to high purity (1R,2S,4R)-(−)-2-[ (2′-{N,N-dimethylamino}-ethoxy)]-2-[phenyl]-1,7,7-tri-methyl -bicyclo[2.2.1]heptane and pharmaceutically acceptable acid addition salts thereof containing not more than 0.2% of (1R,3S,4R)-3-[(2′-{N,N-dimethylamino}-ethyl)]-1 ,7,7-tri-[methyl]-bicyclo[2.2.1]heptane-2-one and/or of a pharmaceutically acceptable acid addition salt thereof.

Abstract: The invention relates to high purity (1R,2S,4R)-(−)-2-[(2′-{N,N-dimethylamino}-ethoxy)]-2-[phenyl]-1,7,7-tri-[methyl]-bicyclo[2.2.1]heptane and pharmaceutically acceptable acid addition salts thereof containing not more than 0.2% of (1R,3S,4R)-3-[(2′-{N,N-dimethylamino}-ethyl)]-1,7,7-tri-[methyl]-bicyclo[2.2.1]heptane-2-one and/or of a pharmaceutically acceptable acid addition salt thereof. Furthermore the invention is concerned with a process for the preparation of these compounds. Moreover the invention relates to medicaments containing 1 or more of these compounds and their use.

Abstract: A process for preparing (1R,2S,4R)-(−)-2-[(2′-[N,N-dimethylamino}-ethoxy)]-2-[phenyl]-1,7,7-tri-[methyl]-bicyclo [2.2.1]heptane and pharmaceutically acceptable acid addition salts thereof with higher yields and higher grades of purity.

Abstract: The invention relates to a new process for the preparation of amlodipine besylate of the Formula ##STR1## Amlodipine besylate of the Formula I is a valuable known blood pressure decreasing antianginal agent.The advantage of the process of the present invention is that it can be carried out in a simple way with high yields and there is no need to isolate the amlodipine base.